mhn romiplostim (Nplate) Coverage & Prior Auth | OpenPayer

Loading...

mhn romiplostim (Nplate) Coverage & Prior Auth | OpenPayer

Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) - Initial Therapy

Covered when ALL of the following are met:

ALL of the following

Diagnosis of HS-ARS
Exposure: Prescriber attestation of suspected or confirmed radiation exposure > 2 Gy> 2 Gy
Prescriber: Prescribed by or in consultation with a hematologist
Dose does not exceed 10 mcg/kg (single SC dose)<= 10 mcg/kg
Approval duration: 4 weeks (1 dose only)

Immune Thrombocytopenia (ITP) - Initial Therapy

Covered when ALL of the following are met:

ALL of the following

Diagnosis of ITP
Prescriber: Prescribed by or in consultation with a hematologist
Age ≥ 1 year>= 1 year
Platelet or bleed: Either current platelet count <30,000/µL (within 30 days) OR member has an active bleed<30,000/µL

Recommended NCCN uses (off-label) - Initial Therapy

Covered when ALL of the following are met:

ALL of the following

Diagnosis of MDS OR chemotherapy-induced thrombocytopenia (CIT)
Prescriber: Prescribed by or in consultation with an oncologist or hematologist
MDS-specific: For MDS: lower-risk IPSS-R AND severe or refractory thrombocytopenia after progression or no response to hypomethylating agents, immunosuppressive therapy, or clinical trial
CIT-specific: For CIT: age ≥ 18 years AND platelets <100,000/µL for ≥3 weeks after last chemotherapy and/or delays in chemotherapy initiation due to thrombocytopeniaplatelets <100,000/µL for >=3 weeks; age >=18

Immune Thrombocytopenia (ITP) - Reauthorization / Continuation

Covered when ALL of the following are met:

ALL of the following

Continuation eligibility: Member currently receiving medication via Centene benefit or previously met initial approval criteria; or continuity of care applies
Response: Member is responding positively to therapy (increase in platelet count from baseline or reduction in bleeding events)
Platelets: Current platelet count (within last 90 days) is <400,000/µL<400,000/µL
Concurrent therapies:

Recommended NCCN uses (off-label) - Reauthorization / Continuation

Covered when ALL of the following are met:

ALL of the following

Current use: Member is currently receiving Nplate via Centene benefit or documentation shows at least 30 days of treatment for MDS or CIT>= 30 days
Response: Member is responding positively to therapy
Concurrent therapies: Not prescribed concurrently with rituximab or another thrombopoietin receptor agonist
Dose change: If dose increase requested, either new dose <= 10 mcg/kg/week OR new dose supported by practice guidelines/literature (evidence required)

Dosing and concurrent therapy criteria

Coverage and dosing when ALL of the following are met

ITP initial dosing and monitoring: Initial dose 1 mcg/kg SC once weekly based on actual body weight; adjust weekly by 1 mcg/kg increments to achieve and maintain platelet count >= 50,000/µL; do not dose if platelet count > 400,000/µL; maximum dose 10 mcg/kg/week.platelet >= 50,000/µL; do not dose if > 400,000/µL

Supports ITP indication dosing and limits

HS-ARS dosing: Administer single 10 mcg/kg SC dose as soon as possible after suspected or confirmed radiation exposure > 2 Gy; maximum dose 10 mcg/kg.exposure > 2 Gy

FDA-approved HS-ARS single-dose indication

Concurrent therapy exclusion: Nplate must not be prescribed concurrently with rituximab, other thrombopoietin receptor agonists, or excluded agents (e.g., spleen tyrosine kinase inhibitors such as Tavalisse) for ITP and for off-label indications per policy updates.

Nplate (romiplostim) is not indicated for treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or for causes of thrombocytopenia other than immune thrombocytopenia (ITP) except where specific NCCN-recommended off-label uses are explicitly addressed in this policy and meet those criteria. Requests for non‑FDA approved indications that are not addressed in this policy will be denied unless sufficient documentation of efficacy and safety is provided per the applicable off‑label use policies.

This policy prohibits concurrent prescribing of Nplate with certain therapies. Specifically, Nplate must not be prescribed concurrently with rituximab, other thrombopoietin receptor agonists, or excluded agents referenced in the policy (for example, spleen tyrosine kinase inhibitors such as Tavalisse). These sequencing and concurrent‑use restrictions apply to ITP and to off‑label uses as noted in the criteria and coding implications.

Use of Nplate solely to attempt to normalize platelet counts is considered not medically necessary. Nplate should be used only when the degree of thrombocytopenia and the clinical condition increase the risk for bleeding or when other coverage criteria for an indicated or covered off‑label use are met.

Concurrent use of Nplate with the following therapies is explicitly disallowed under this policy: rituximab, other thrombopoietin receptor agonists, and, as updated, spleen tyrosine kinase inhibitors (e.g., Tavalisse). Requests that propose simultaneous administration with these agents will trigger non‑coverage or denial per the policy operational rules.

Covered Regimens and Dose Limits

Indication	Regimen / Limit
MDS or chemotherapy‑induced thrombocytopenia (CIT) when meeting NCCN criteria	Dose must not exceed 10 mcg/kg per week OR dose supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence)

Indication	Requirement / Exclusions
Chemotherapy‑induced thrombocytopenia (CIT)	Use limited to adult patients (≥18 years) per NCCN guidance; Nplate must not be prescribed concurrently with rituximab or another thrombopoietin receptor agonist

Provider Actions, Prior Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required. Provider must document that the member meets all approval criteria for the requested indication. Submit supporting documentation such as office chart notes, laboratory results (including current platelet counts), actual body weight for dosing, and any records demonstrating prior therapies or reasons for intolerance/contraindication. Approval duration: 6 months unless otherwise specified.

Affected HCPCS: J2802 (romiplostim) — PA must reflect sequencing and exclusion rules
Document actual body weight for dosing calculations
Include current platelet count (within 30 days) and bleeding status
Provide prior therapy records showing failure of systemic corticosteroids or intolerance/contraindication and failure of immune globulin when applicable

Denial Risk

Non‑FDA Indications — Evidence Required

Requests for indications that are non–FDA approved and not addressed in this policy will be denied unless there is sufficient documentation of efficacy and safety per the applicable off-label use policies (e.g., CP.CPA.09 for commercial, HIM.PA.154 for marketplace, CP.PMN.53 for Medicaid) or other evidence of coverage documents. Provide clinical literature or case documentation supporting the off-label use when applicable.

Billing Rule

Weight, Platelet Monitoring & Billing

Weight, platelet monitoring, and billing must be documented. Use the member's actual body weight to calculate the weekly romiplostim dose (initial 1 mcg/kg SC weekly, titrate by 1 mcg/kg increments to maintain platelet count ≥ 50,000/µL; maximum 10 mcg/kg/week). Do not dose if platelet count > 400,000/µL. Record platelet counts used for dosing decisions and include dates. For billing, ensure appropriate HCPCS (e.g., J2802) units reflect micrograms administered and align with documented weight-based dosing.

Initial dose: 1 mcg/kg SC once weekly based on actual body weight
Titrate by 1 mcg/kg to achieve platelet count ≥ 50,000/µL; maximum 10 mcg/kg/week
Do not dose if platelet count > 400,000/µL
Document platelet counts and dates in submitted records
Bill using HCPCS J2802 with units matching micrograms administered

Step Therapy

Step Therapy / Prior Treatments

Step therapy / prior treatments are required for ITP. Member must have documentation of failure of a systemic corticosteroid OR intolerance/contraindication to systemic corticosteroids plus failure of an immune globulin (unless immune globulin is contraindicated or causes clinically significant adverse effects). Appendix B lists therapeutic alternatives such as corticosteroids; these alternatives should be tried per regimen and documented unless contraindicated.

Required prior treatment: failure of systemic corticosteroid; OR intolerance/contraindication to corticosteroids plus failure of immune globulin
Document prior treatment dates, doses, responses, and reasons for discontinuation or intolerance
Note: prior authorization may be required for immune globulins

Documentation Required

Sequencing Constraints / Concurrent Therapy Exclusions

Sequencing constraints — Nplate (romiplostim) must not be prescribed concurrently with rituximab, another thrombopoietin receptor agonist (e.g., eltrombopag/Promacta®, avatrombopag/Doptelet®, lusutrombopag/Mulpleta®), or a spleen tyrosine kinase inhibitor (e.g., fostamatinib/Tavalisse™). Prior authorization will be denied or limited when requests indicate concurrent use with excluded agents. Ensure submitted regimen clarifies sequencing and any washout periods as clinically appropriate.

Concurrent use prohibited with: rituximab; other TPO‑RAs (Promacta®, Doptelet®, Mulpleta®); spleen tyrosine kinase inhibitors (Tavalisse™)
PA requests for romiplostim with HCPCS J2802 must reflect these exclusions
If switching therapies, document dates of last dose of prior agent and rationale for transition